Navigation Links
Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
Date:2/28/2008

developing ANA773 as a novel therapy for patients with cancer. We anticipate identifying the dose and schedule for Phase II investigation by the end of this year."

About ANA773

ANA773 is an orally administered prodrug of a novel TLR7-specific agonist. Pharmacology studies have shown that ANA773 can elicit desired immune responses and components of the response can be modulated by both dose and schedule of administration.

Data presented at the AACR-NCI-EORTC meeting in October 2007 showed that activation of TLR7 by the biologically active metabolite of ANA773 initiates a cascade of immune stimulatory events that has the potential to mediate anti-tumor activity by the induction of cytolytic activity by CD8 T cells against tumor cells and cytolytic activity of NK cells against tumor cells directly or through antibody-dependent cellular cytotoxicity (ADCC). Anadys also demonstrated that the immunostimulatory responses can be modulated by schedule of administration. Earlier in 2007, data presented at the AACR meeting showed that ANA773 and its active metabolite stimulate secretion of interferon alpha and other cytokines as well as enhance rituximab-mediated ADCC against transformed B cells.

About TLR7 agonists in cancer therapy

The potential benefits of the TLR7 mechanism in cancer therapy arise from the fundamental role of this receptor in immune activation. The host immune system, once activated, plays an essential role in controlling the ability of cancer cells to grow, invade and metastasize. Immunotherapy has had some success in treating selected tumors, and the potential to harness the immune system as a therapeutic modality remains of great interest to many oncologists.

TLR7 agonists are of particular interest because there is precedent for their use in cancer. Small molecule ligands for this receptor have been identified, including topical imiquimod (Aldara(R)) which is approved for the treatment of basal cell carcinoma i
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
2. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
7. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
8. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
11. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... while ... ... TSX symbol: SBS, CALGARY, March 17 /PRNewswire-FirstCall/ - SemBioSys Genetics ... and cardiovascular diseases, today announced its,operational and financial results for the ...
... measuring airway inflammation poised to ... for improved control., MENLO PARK, Calif., March 17 ... Insight eNO system has received,clearance to market by the ... system measures exhaled nitric oxide (eNO), which is a,well-established ...
... 17 , - New Executives Appointed in ... Development Towards Commercialization, QuoNova LLC, which is ... in the global fight against bacterial,infection and damage ... executives in global roles to support its next ...
Cached Biology Technology:SemBioSys announces 2007 financial and operational results 2SemBioSys announces 2007 financial and operational results 3SemBioSys announces 2007 financial and operational results 4SemBioSys announces 2007 financial and operational results 5SemBioSys announces 2007 financial and operational results 6SemBioSys announces 2007 financial and operational results 7SemBioSys announces 2007 financial and operational results 8SemBioSys announces 2007 financial and operational results 9SemBioSys announces 2007 financial and operational results 10SemBioSys announces 2007 financial and operational results 11SemBioSys announces 2007 financial and operational results 12SemBioSys announces 2007 financial and operational results 13Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management 2Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management 3QuoNova Global Executive Appointments 2QuoNova Global Executive Appointments 3QuoNova Global Executive Appointments 4
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... and security consultant, Apollo Robbins for the ... wallet.  Apollo Robbins will ... th , 2015, demonstrating some of his famous theft ...
(Date:12/19/2014)... 18, 2014 Research and Markets ( ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter ... of 3.6% from 2014 to 2019. Although the U.S. ... Canada is expected to grow at ...
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... its efforts to make it easier to detect ... supply chain. Today the agency started ... marking. The capability will validate the authenticity of ... supply chain. The new quality control measures will ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... has shown for the first time that sulforaphane, the powerful ... compound by bacteria in the lower gut and absorbed into ... will be able to enhance the activity of these bacteria ... a U of I professor of human nutrition. "It,s ...
... PARK, Md. - Offshore wind power offers a feasible ... goals, but presents some economic and political hurdles, concludes ... for Integrative Environmental Research (CIER). The study, " ... feasibility assessment to date of developing and operating wind ...
... Central Africa 65 million years ago was a low-elevation tropical ... region,s mammals browsed and hunted beneath the canopy of a ... at that time is weak and far from convincing, says ... Fossil pollen from Central and West Africa provide no ...
Cached Biology News:Discovery may help scientists boost broccoli’s cancer-fighting power 2Offshore wind a 'mixed bag': University of Maryland study 2Offshore wind a 'mixed bag': University of Maryland study 3Evidence is weak for tropical rainforest 65 million years ago in Africa's low-latitudes 2Evidence is weak for tropical rainforest 65 million years ago in Africa's low-latitudes 3
... Weight Markers, 37 kBq, 1 uCi. Carbon-14 ... of the sample on Western blots.The Rainbow-labeled ... migration in the gel and on the ... without Rainbow-labeling is 0.37-3.7 MBq/mg (10-100 uCi/mg) ...
in vitro Translation, Accessory Products...
NM522 contains an F episome, which is required for production of ssDNA and for blue/white color selection. To maintain the F, NM522 should be grown on minimal (M-9) medium....
... The Zero Blunt TOPO ... Sequencing is designed for ... of blunt-end PCR products. ... 5-minute TOPO Cloning and ...
Biology Products: